Hassane, Duane C

Publications

Sort by

Co-Author Network

selected publications

Phased Variant-Supported Circulating Tumor DNA as a Prognostic Biomarker After First-Line Treatment in Large B-Cell Lymphoma: Findings From the DIRECT Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2025 Academic Article GET IT
Immune Checkpoint Inhibitor Therapy and Associations with Clonal Hematopoiesis. International journal of molecular sciences. 2024 Academic Article GET IT
Times cited: 7
Genome and clonal hematopoiesis stability contrasts with immune, cfDNA, mitochondrial, and telomere length changes during short duration spaceflight. Precision clinical medicine. 2024 Academic Article GET IT
Times cited: 21
Correction: Integrative analysis identifies an older female-linked AML patient group with better risk in ECOG-ACRIN Cancer Research Group's clinical trial E3999. 2023 GET IT
Paired bone marrow and peripheral blood samples demonstrate lack of widespread dissemination of some CH clones. Blood advances. 2023 Academic Article GET IT
Times cited: 9
Integrative analysis identifies an older female-linked AML patient group with better risk in ECOG-ACRIN Cancer Research Group's clinical trial E3999. Blood cancer journal. 2022 Letter GET IT
Times cited: 1
Allogeneic TCRαβ deficient CAR T-cells targeting CD123 in acute myeloid leukemia. Nature communications. 2022 Academic Article GET IT
Times cited: 59
Matrix stiffness enhances cancer-macrophage interactions and M2-like macrophage accumulation in the breast tumor microenvironment. Acta biomaterialia. 2022 Academic Article GET IT
Times cited: 58
Mutant PPM1D- and TP53-Driven Hematopoiesis Populates the Hematopoietic Compartment in Response to Peptide Receptor Radionuclide Therapy. JCO precision oncology. 2022 Academic Article GET IT
Times cited: 34
Fundamental Biological Features of Spaceflight: Advancing the Field to Enable Deep-Space Exploration. 2021 GET IT
Times cited: 12
Patient-Derived Bone Marrow Spheroids Reveal Leukemia-Initiating Cells Supported by Mesenchymal Hypoxic Niches in Pediatric B-ALL. Frontiers in immunology. 2021 Academic Article GET IT
Times cited: 20
Targeting the epichaperome as an effective precision medicine approach in a novel PML-SYK fusion acute myeloid leukemia. NPJ precision oncology. 2021 Academic Article GET IT
Times cited: 29
Genomic and evolutionary portraits of disease relapse in acute myeloid leukemia. Leukemia. 2021 Academic Article GET IT
Times cited: 15
Clonal hematopoiesis before, during, and after human spaceflight. 2021 GET IT
Times cited: 1
Clonal Hematopoiesis Before, During, and After Human Spaceflight. Cell reports. 2020 Academic Article GET IT
Times cited: 47
Fundamental Biological Features of Spaceflight: Advancing the Field to Enable Deep-Space Exploration. Cell. 2020 Review GET IT
Times cited: 349
Plasma Cell Myeloma Presenting With Amyloid-Laden Crystal-Negative Histiocytosis. 2020 GET IT
Times cited: 2
Clonal Hematopoiesis and Premalignant Diseases. Cold Spring Harbor perspectives in medicine. 2020 Review GET IT
Times cited: 18
Cranberry A-type proanthocyanidins selectively target acute myeloid leukemia cells. Blood advances. 2019 Academic Article GET IT
Times cited: 9
Clonal Hematopoiesis and risk of Acute Myeloid Leukemia. Best practice & research. Clinical haematology. 2019 Information Resource GET IT
Times cited: 7
Randomized trial of 10 days of decitabine ± bortezomib in untreated older patients with AML: CALGB 11002 (Alliance). Blood advances. 2018 Academic Article GET IT
Times cited: 46
Somatic mutations precede acute myeloid leukemia years before diagnosis. Nature medicine. 2018 Academic Article GET IT
Times cited: 529
Phase I trial of plerixafor combined with decitabine in newly diagnosed older patients with acute myeloid leukemia. Haematologica. 2018 Academic Article GET IT
Times cited: 42
Single-cell RNA sequencing reveals a signature of sexual commitment in malaria parasites. Nature. 2017 Academic Article GET IT
Times cited: 170
Selection and characterization of antibody clones are critical for accurate flow cytometry-based monitoring of CD123 in acute myeloid leukemia. Leukemia & lymphoma. 2017 Letter GET IT
Times cited: 13
CD25 expression and outcomes in older patients with acute myelogenous leukemia treated with plerixafor and decitabine. Leukemia & lymphoma. 2017 Academic Article GET IT
Times cited: 12
Myelodysplastic Syndrome, Unclassifiable (MDS-U) With 1% Blasts Is a Distinct Subgroup of MDS-U With a Poor Prognosis. American journal of clinical pathology. 2017 Academic Article GET IT
Times cited: 15
Oligomonocytic chronic myelomonocytic leukemia (chronic myelomonocytic leukemia without absolute monocytosis) displays a similar clinicopathologic and mutational profile to classical chronic myelomonocytic leukemia. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc. 2017 Academic Article GET IT
Times cited: 33
The effect of initial molecular profile on response to recombinant interferon-α (rIFNα) treatment in early myelofibrosis. Cancer. 2017 Academic Article GET IT
Times cited: 28
Minimal Residual Disease Monitoring of Acute Myeloid Leukemia by Massively Multiplex Digital PCR in Patients with NPM1 Mutations. The Journal of molecular diagnostics : JMD. 2017 Academic Article GET IT
Times cited: 76
Identification of a nucleoside analog active against adenosine kinase-expressing plasma cell malignancies. The Journal of clinical investigation. 2017 Academic Article GET IT
Times cited: 9
Minimal residual disease in acute myelogenous leukemia. International journal of laboratory hematology. 2017 Review GET IT
Times cited: 42
Epigenetic Identity in AML Depends on Disruption of Nonpromoter Regulatory Elements and Is Affected by Antagonistic Effects of Mutations in Epigenetic Modifiers. Cancer discovery. 2017 Academic Article GET IT
Times cited: 111
Matrix stiffening promotes a tumor vasculature phenotype. Proceedings of the National Academy of Sciences of the United States of America. 2016 Academic Article GET IT
Times cited: 354
Distinct evolution and dynamics of epigenetic and genetic heterogeneity in acute myeloid leukemia. Nature medicine. 2016 Academic Article GET IT
Times cited: 321
Selective activity of the histone deacetylase inhibitor AR-42 against leukemia stem cells: a novel potential strategy in acute myelogenous leukemia. Molecular cancer therapeutics. 2014 Academic Article GET IT
Times cited: 52
Novel mTOR inhibitory activity of ciclopirox enhances parthenolide antileukemia activity. Experimental hematology. 2013 Academic Article GET IT
Times cited: 38
Gene signature critical to cancer phenotype as a paradigm for anticancer drug discovery. Oncogene. 2012 Academic Article GET IT
Times cited: 5
Gene sets identified with oncogene cooperativity analysis regulate in vivo growth and survival of leukemia stem cells. Cell stem cell. 2012 Academic Article GET IT
Times cited: 53
Acute myelogenous leukemia stem cells: from Bench to Bedside. Cancer letters. 2012 Review GET IT
Times cited: 43
Chemical genomic screening reveals synergism between parthenolide and inhibitors of the PI-3 kinase and mTOR pathways. Blood. 2010 Academic Article GET IT
Times cited: 71
Discovery of agents that eradicate leukemia stem cells using an in silico screen of public gene expression data. Blood. 2008 Academic Article GET IT
Times cited: 172
An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cells. Blood. 2007 Academic Article GET IT
Times cited: 370
Tat-calpastatin fusion proteins transduce primary rat cortical neurons but do not inhibit cellular calpain activity. Experimental neurology. 2004 Academic Article GET IT
Times cited: 22
Interactions of Campylobacter jejuni cytolethal distending toxin subunits CdtA and CdtC with HeLa cells. Infection and immunity. 2003 Academic Article GET IT
Times cited: 107
Campylobacter jejuni cytolethal distending toxin promotes DNA repair responses in normal human cells. Infection and immunity. 2003 Academic Article GET IT
Times cited: 94
Cytolethal distending toxin demonstrates genotoxic activity in a yeast model. Infection and immunity. 2001 Academic Article GET IT
Times cited: 69

more ...

less ...

Research

Sort by

Co-investigator Network

Funding awarded

Pre-malignant mutation landscape and risk factors for progression to hematologic cancers awarded by National Cancer Institute Co-Principal Investigator 2021 - 2027

more ...

less ...

Background

education and training

Ph.D., University of Kentucky 2002
M.S., University of Rochester 1997
B.S., University of Rochester 1995

Contact

full name

Duane C Hassane

primary email

duh2002@med.cornell.edu

webpage

https://vivo.med.cornell.edu/individual/n32011 (no url provided for link)

VIVO Weill Cornell Medical College

Duane C Hassane Assistant Professor of Computational Biomedicine in Medicine (Courtesy)

Publications

selected publications

Research

Funding awarded

Background

education and training

Contact

full name

primary email

webpage

Phone

Publications

selected publications

Research

Funding awarded

Background

education and training

Contact

full name

primary email

webpage